Match!
Kensei Tobinai
Juntendo University
540Publications
45H-index
12.7kCitations
Publications 554
Newest
#1Koji IzutsuH-Index: 30
#2Yosuke MinamiH-Index: 13
Last.Kensei TobinaiH-Index: 45
view all 15 authors...
Patients with indolent non-Hodgkin lymphoma (iNHL) typically respond to first-line immunochemotherapy, but relapse is common. Treatment options for relapsed iNHL include chemotherapy ± rituximab and rituximab monotherapy. Lenalidomide plus rituximab (R2) is an immunomodulatory regimen that enhances rituximab-mediated cytotoxicity and improves clinical activity in iNHL. AUGMENT was a double-blind phase III randomized trial of R2 vs. rituximab + placebo (R-placebo) in patients with relapsed/refrac...
Source
Source
#1Masaki Ri (Nagoya City University)H-Index: 17
#2Shinsuke Iida (Nagoya City University)H-Index: 38
Last.Hirokazu NagaiH-Index: 16
view all 18 authors...
Source
#1Kerry J. Savage (UBC: University of British Columbia)H-Index: 52
#2Steven M. Horwitz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 45
Last.Swaminathan Padmanabhan Iyer (University of Texas MD Anderson Cancer Center)H-Index: 16
view all 23 authors...
Source
#1Saaya Tsutsue (Celgene)
#2Kensei TobinaiH-Index: 45
view all 4 authors...
Source
#1Satoko Morishima (University of the Ryukyus)H-Index: 13
#2Kenji Ishitsuka (Kadai: Kagoshima University)H-Index: 34
Last.Kensei TobinaiH-Index: 45
view all 16 authors...
Source
#1Youn H. Kim (Stanford University)H-Index: 55
#2Martine BagotH-Index: 57
Last.Lubomir SokolH-Index: 30
view all 70 authors...
Source
#2Nathan Fowler (University of Texas MD Anderson Cancer Center)H-Index: 32
Last.Franck MorschhauserH-Index: 49
view all 36 authors...
Source
#1Makoto Yamagishi (UTokyo: University of Tokyo)H-Index: 12
#2Makoto Hori (UTokyo: University of Tokyo)H-Index: 4
Last.Kaoru Uchimaru (UTokyo: University of Tokyo)H-Index: 21
view all 20 authors...
Summary Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy for H3K27me3-high malignancies harboring EZH2WT/WT has yet been established. We explore epigenome and transcriptome in EZH2WT/WT and EZH2WT/Mu aggressive lymphomas and show that mutual interference and compensatory function of co-expressed EZH1 and EZH2 rearrange their own genome-wide distribution, thereby establishing restricted chromatin and gene expression signatures. Direct comparison of...
Source
#1Shinsuke Iida (Nagoya City University)H-Index: 38
#2Toshio WatanabeH-Index: 41
Last.Kensei TobinaiH-Index: 45
view all 17 authors...
2 CitationsSource
12345678910